PTIX (Protagenic Therapeutics) Net Income From Continuing Operations: $-5.16 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PTIX Protagenic Therapeutics Inc PTIX
26 GF Score
Price $0.81
! 2 Warning Signs
View Full Analysis

What is Protagenic Therapeutics Net Income From Continuing Operations?

Protagenic Therapeutics PTIX -2.41% 26 Net Income From Continuing Operations is $-5.16 Mil as of Dec. 2025. GuruFocus rates PTIX with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Protagenic Therapeutics's net income from continuing operations for the three months ended in Dec. 2025 was $2.21 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-5.16 Mil.

Protagenic Therapeutics Net Income From Continuing Operations Historical Data

* Premium members only.

The historical data trend for Protagenic Therapeutics's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protagenic Therapeutics Net Income From Continuing Operations Chart

Protagenic Therapeutics Annual Data
Trend Dec10 Jun14 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.75 -2.55 -4.52 -3.56 -5.00

Protagenic Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.64 -1.55 -5.06 -0.87 2.21
PTIX
26GF Score
Protagenic Therapeutics Inc PTIX
Net Income From Continuing Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protagenic Therapeutics Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income From Continuing Operations of $-5.16 Mil mean?
Protagenic Therapeutics (PTIX) has a Net Income From Continuing Operations of $-5.16 Mil as of Dec. 2025. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Protagenic Therapeutics and its competitors.
Is Protagenic Therapeutics' Net Income From Continuing Operations too high?
Protagenic Therapeutics' current Net Income From Continuing Operations is $-5.16 Mil. Overall, Protagenic Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Protagenic Therapeutics' Net Income From Continuing Operations compare to SCNI and DCOY?
Protagenic Therapeutics' Net Income From Continuing Operations of $-5.16 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Biotechnology company?
A good Net Income From Continuing Operations depends on the Biotechnology industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Protagenic Therapeutics and its competitors. Protagenic Therapeutics's current Net Income From Continuing Operations is $-5.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagenic Therapeutics stock overvalued right now?
Protagenic Therapeutics (PTIX) has a current Net Income From Continuing Operations of $-5.16 Mil. The current Net Income From Continuing Operations is $-5.16 Mil. Protagenic Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For Protagenic Therapeutics (PTIX), the current Net Income From Continuing Operations is $-5.16 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Protagenic Therapeutics Business Description

Address 149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
26GF Score

Get the complete analysis for PTIX

Net Income From Continuing Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.81
Price